Elizabeth Anderson
Stock Analyst at Evercore ISI Group
(2.11)
# 2,892
Out of 4,944 analysts
123
Total ratings
43.94%
Success rate
-6.6%
Average return
Main Sectors:
Stocks Rated by Elizabeth Anderson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CAH Cardinal Health | Maintains: Outperform | $200 → $190 | $148.40 | +28.03% | 9 | Aug 13, 2025 | |
| FTRE Fortrea Holdings | Maintains: In-Line | $5 → $7 | $8.04 | -12.94% | 9 | Aug 8, 2025 | |
| HNGE Hinge Health | Maintains: Outperform | $50 → $60 | $57.73 | +3.93% | 1 | Aug 6, 2025 | |
| LH Labcorp Holdings | Maintains: Outperform | $285 → $300 | $271.08 | +10.67% | 6 | Jul 25, 2025 | |
| TDOC Teladoc Health | Maintains: In-Line | $7 → $8 | $7.39 | +8.25% | 4 | Jul 9, 2025 | |
| PRVA Privia Health Group | Maintains: Outperform | $30 → $28 | $20.99 | +33.40% | 4 | Jul 9, 2025 | |
| NVST Envista Holdings | Maintains: Outperform | $19 → $23 | $20.81 | +10.55% | 4 | Jul 9, 2025 | |
| MCK McKesson | Maintains: Outperform | $760 → $800 | $664.68 | +20.36% | 6 | Jul 9, 2025 | |
| IQV IQVIA Holdings | Maintains: Outperform | $170 → $180 | $188.10 | -4.31% | 6 | Jul 9, 2025 | |
| HCAT Health Catalyst | Maintains: In-Line | $5 → $4 | $3.06 | +30.72% | 7 | Jul 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $5 → $3 | $1.05 | +187.08% | 5 | Jul 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $50 → $70 | $63.90 | +9.55% | 8 | Jul 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $165 → $200 | $144.00 | +38.89% | 13 | May 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $175 → $180 | $177.85 | +1.21% | 3 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $60 → $65 | $66.93 | -2.88% | 6 | Jan 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $9 → $12 | $11.89 | +0.93% | 13 | Jan 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $20 | $13.52 | +47.93% | 7 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $36 | $35.14 | +2.45% | 4 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $68 → $26 | $6.03 | +335.32% | 3 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $35 → $15 | $3.55 | +322.54% | 3 | Mar 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $11 | $2.04 | +439.22% | 2 | Jan 4, 2022 |
Cardinal Health
Aug 13, 2025
Maintains: Outperform
Price Target: $200 → $190
Current: $148.40
Upside: +28.03%
Fortrea Holdings
Aug 8, 2025
Maintains: In-Line
Price Target: $5 → $7
Current: $8.04
Upside: -12.94%
Hinge Health
Aug 6, 2025
Maintains: Outperform
Price Target: $50 → $60
Current: $57.73
Upside: +3.93%
Labcorp Holdings
Jul 25, 2025
Maintains: Outperform
Price Target: $285 → $300
Current: $271.08
Upside: +10.67%
Teladoc Health
Jul 9, 2025
Maintains: In-Line
Price Target: $7 → $8
Current: $7.39
Upside: +8.25%
Privia Health Group
Jul 9, 2025
Maintains: Outperform
Price Target: $30 → $28
Current: $20.99
Upside: +33.40%
Envista Holdings
Jul 9, 2025
Maintains: Outperform
Price Target: $19 → $23
Current: $20.81
Upside: +10.55%
McKesson
Jul 9, 2025
Maintains: Outperform
Price Target: $760 → $800
Current: $664.68
Upside: +20.36%
IQVIA Holdings
Jul 9, 2025
Maintains: Outperform
Price Target: $170 → $180
Current: $188.10
Upside: -4.31%
Health Catalyst
Jul 9, 2025
Maintains: In-Line
Price Target: $5 → $4
Current: $3.06
Upside: +30.72%
Jul 9, 2025
Maintains: In-Line
Price Target: $5 → $3
Current: $1.05
Upside: +187.08%
Jul 9, 2025
Upgrades: Outperform
Price Target: $50 → $70
Current: $63.90
Upside: +9.55%
May 1, 2025
Maintains: Outperform
Price Target: $165 → $200
Current: $144.00
Upside: +38.89%
Apr 23, 2025
Maintains: In-Line
Price Target: $175 → $180
Current: $177.85
Upside: +1.21%
Jan 27, 2025
Maintains: Outperform
Price Target: $60 → $65
Current: $66.93
Upside: -2.88%
Jan 13, 2025
Maintains: In-Line
Price Target: $9 → $12
Current: $11.89
Upside: +0.93%
Jan 7, 2025
Downgrades: In-Line
Price Target: $20
Current: $13.52
Upside: +47.93%
Nov 7, 2024
Maintains: Outperform
Price Target: $32 → $36
Current: $35.14
Upside: +2.45%
Mar 16, 2022
Maintains: In-Line
Price Target: $68 → $26
Current: $6.03
Upside: +335.32%
Mar 2, 2022
Downgrades: In-Line
Price Target: $35 → $15
Current: $3.55
Upside: +322.54%
Jan 4, 2022
Downgrades: In-Line
Price Target: $11
Current: $2.04
Upside: +439.22%